Regenics Convenes Inaugural Scientific Advisory Board

Regenics is proud to announce the successful convening of its first Scientific Advisory Board (SAB) meeting, marking a significant milestone in the company’s mission to advance next-generation wound healing technologies.

The SAB brings together leading experts in wound care, clinical medicine and research, including Dr. Christoph Wallner, Dr. Davíð Jensson, and Professor Dr. Guttorm Haraldsen, alongside Regenics’ leadership team: CEO Jostein Grip, Chief Scientific Officer Karin Gilljam and Chief Medical Officer Karl Bryn.

The inaugural meeting focused on Regenics’ advanced wound healing platform, including both immediate and long-term strategic priorities. Key topics included optimizing the application and clinical use of Collex, Regenics’ proprietary wound dressing, as well as exploring future directions for the company’s HTX technology.

Board members provided valuable insights on clinical best practices, product differentiation and regulatory considerations, emphasizing the importance of practical solutions for clinicians and improved outcomes for patients. We are grateful for the commitment and expertise of our SAB members and look forward to their continued contributions.

For more information about Regenics and our scientific advisory board, please contact CEO Jostein Grip atjg@regenics.no.

Tags: